Risperidone in the management of disruptive behavior disorders

Gahan J. Pandina, Michael G. Aman, Robert L Findling

Research output: Contribution to journalArticle

Abstract

Disruptive behavior disorders (DBDs) represent a spectrum of disorders, including conduct disorder and oppositional-defiant disorder. The atypical antipsychotic risperidone may be useful for the management of patients with DBDs. Clinical data on risperidone have demonstrated efficacy and satisfactory tolerability in improving angry, aggressive, self-injurious, and disruptive symptoms and behavior in children with pervasive developmental disorders and mood disorders. This paper reviews the results of recent studies that have evaluated the efficacy and safety of risperidone in the treatment of pediatric patients with DBDs. Because concerns have been raised regarding the safety of atypical antipsychotic treatment in pediatric patients, this paper further evaluates safety risks by presenting newly completed analyses of movement disorders, prolactin concentrations, body weight, and cognitive function data from short- and long-term studies in this patient population. A comprehensive review of all of the findings suggests that risperidone is an effective and well-tolerated treatment option for children and adolescents with DBDs. As with all antipsychotics, practitioners should monitor young patients' growth, weight, sexual maturation, and metabolic parameters.

Original languageEnglish (US)
Pages (from-to)379-392
Number of pages14
JournalJournal of Child and Adolescent Psychopharmacology
Volume16
Issue number4
DOIs
StatePublished - Aug 2006
Externally publishedYes

Fingerprint

Attention Deficit and Disruptive Behavior Disorders
Risperidone
Antipsychotic Agents
Safety
Pediatrics
Sexual Maturation
Conduct Disorder
Movement Disorders
Mood Disorders
Prolactin
Cognition
Therapeutics
Body Weight
Weights and Measures
Growth
Population

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Psychiatry and Mental health
  • Pediatrics, Perinatology, and Child Health
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Risperidone in the management of disruptive behavior disorders. / Pandina, Gahan J.; Aman, Michael G.; Findling, Robert L.

In: Journal of Child and Adolescent Psychopharmacology, Vol. 16, No. 4, 08.2006, p. 379-392.

Research output: Contribution to journalArticle

@article{b63be009f74841ac99bb31b600ed4025,
title = "Risperidone in the management of disruptive behavior disorders",
abstract = "Disruptive behavior disorders (DBDs) represent a spectrum of disorders, including conduct disorder and oppositional-defiant disorder. The atypical antipsychotic risperidone may be useful for the management of patients with DBDs. Clinical data on risperidone have demonstrated efficacy and satisfactory tolerability in improving angry, aggressive, self-injurious, and disruptive symptoms and behavior in children with pervasive developmental disorders and mood disorders. This paper reviews the results of recent studies that have evaluated the efficacy and safety of risperidone in the treatment of pediatric patients with DBDs. Because concerns have been raised regarding the safety of atypical antipsychotic treatment in pediatric patients, this paper further evaluates safety risks by presenting newly completed analyses of movement disorders, prolactin concentrations, body weight, and cognitive function data from short- and long-term studies in this patient population. A comprehensive review of all of the findings suggests that risperidone is an effective and well-tolerated treatment option for children and adolescents with DBDs. As with all antipsychotics, practitioners should monitor young patients' growth, weight, sexual maturation, and metabolic parameters.",
author = "Pandina, {Gahan J.} and Aman, {Michael G.} and Findling, {Robert L}",
year = "2006",
month = "8",
doi = "10.1089/cap.2006.16.379",
language = "English (US)",
volume = "16",
pages = "379--392",
journal = "Journal of Child and Adolescent Psychopharmacology",
issn = "1044-5463",
publisher = "Mary Ann Liebert Inc.",
number = "4",

}

TY - JOUR

T1 - Risperidone in the management of disruptive behavior disorders

AU - Pandina, Gahan J.

AU - Aman, Michael G.

AU - Findling, Robert L

PY - 2006/8

Y1 - 2006/8

N2 - Disruptive behavior disorders (DBDs) represent a spectrum of disorders, including conduct disorder and oppositional-defiant disorder. The atypical antipsychotic risperidone may be useful for the management of patients with DBDs. Clinical data on risperidone have demonstrated efficacy and satisfactory tolerability in improving angry, aggressive, self-injurious, and disruptive symptoms and behavior in children with pervasive developmental disorders and mood disorders. This paper reviews the results of recent studies that have evaluated the efficacy and safety of risperidone in the treatment of pediatric patients with DBDs. Because concerns have been raised regarding the safety of atypical antipsychotic treatment in pediatric patients, this paper further evaluates safety risks by presenting newly completed analyses of movement disorders, prolactin concentrations, body weight, and cognitive function data from short- and long-term studies in this patient population. A comprehensive review of all of the findings suggests that risperidone is an effective and well-tolerated treatment option for children and adolescents with DBDs. As with all antipsychotics, practitioners should monitor young patients' growth, weight, sexual maturation, and metabolic parameters.

AB - Disruptive behavior disorders (DBDs) represent a spectrum of disorders, including conduct disorder and oppositional-defiant disorder. The atypical antipsychotic risperidone may be useful for the management of patients with DBDs. Clinical data on risperidone have demonstrated efficacy and satisfactory tolerability in improving angry, aggressive, self-injurious, and disruptive symptoms and behavior in children with pervasive developmental disorders and mood disorders. This paper reviews the results of recent studies that have evaluated the efficacy and safety of risperidone in the treatment of pediatric patients with DBDs. Because concerns have been raised regarding the safety of atypical antipsychotic treatment in pediatric patients, this paper further evaluates safety risks by presenting newly completed analyses of movement disorders, prolactin concentrations, body weight, and cognitive function data from short- and long-term studies in this patient population. A comprehensive review of all of the findings suggests that risperidone is an effective and well-tolerated treatment option for children and adolescents with DBDs. As with all antipsychotics, practitioners should monitor young patients' growth, weight, sexual maturation, and metabolic parameters.

UR - http://www.scopus.com/inward/record.url?scp=33750601586&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750601586&partnerID=8YFLogxK

U2 - 10.1089/cap.2006.16.379

DO - 10.1089/cap.2006.16.379

M3 - Article

C2 - 16958564

AN - SCOPUS:33750601586

VL - 16

SP - 379

EP - 392

JO - Journal of Child and Adolescent Psychopharmacology

JF - Journal of Child and Adolescent Psychopharmacology

SN - 1044-5463

IS - 4

ER -